triazoles has been researched along with Rheumatoid Arthritis in 70 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (4.29) | 18.2507 |
| 2000's | 5 (7.14) | 29.6817 |
| 2010's | 26 (37.14) | 24.3611 |
| 2020's | 36 (51.43) | 2.80 |
| Authors | Studies |
|---|---|
| Ariani, A; Becciolini, A; Di Donato, E; Lucchini, G; Mozzani, F; Riva, M; Santilli, D | 1 |
| Bartok, B; Besuyen, R; Burmester, GR; Chen, K; Genovese, MC; Gottenberg, JE; Jahreis, A; Jiang, D; Kivitz, A; Matzkies, F; Takeuchi, T; Tanaka, Y; Winthrop, KL | 1 |
| Amano, K; Atsumi, T; Bae, SC; Bartok, B; Combe, BG; Guo, Y; Ishiguro, N; Keystone, EC; Kivitz, AJ; Kondo, A; Matsubara, T; Matzkies, F; Nash, P; Pechonkina, A; Sugiyama, E; Sundy, JS; Takeuchi, T; Tanaka, Y; Tasset, C; Yamaoka, K; Ye, L | 1 |
| Amano, K; Atsumi, T; Bartok, B; Burmester, GR; Ching, DWT; Guo, Y; Ishiguro, N; Kondo, A; Matsubara, T; Messina, OD; Pechonkina, A; Sugiyama, E; Sundy, JS; Takeuchi, T; Tanaka, Y; Tasset, C; Westhovens, R; Yamaoka, K; Yin, Z | 1 |
| Bingham, CO; Combe, B; Hu, H; Khalid, JM; Lee, SJ; Nash, P; Walker, D; Ye, L | 1 |
| Anderson, K; Bartok, B; Bellanti, F; Chang, P; Chuang, SM; Comisar, C; Kearney, BP; Mathias, A; Meng, A; Nelson, C; Ni, L | 1 |
| Anderson, K; Namour, F; Nelson, C; Tasset, C | 1 |
| Westhovens, R | 2 |
| Lee, YH; Song, GG | 4 |
| Dowty, ME; Hegen, M; Jesson, MI; Katkade, V; Lin, TH; Martin, DA; Menon, S; Telliez, JB | 1 |
| Bonovas, S; Danese, S; Lasa, JS; Olivera, PA; Peyrin-Biroulet, L | 1 |
| Abd Eldaim, MA; Abdallah, AEM; Abdel-Daim, MM; Abdelaziz, SAM; Abdul Rashid, S; Abdullah, AS; Abdullah, LC; Abramson, MJ; Ahmed, HB; Ahmed, MM; Ahn, YC; Alexander, DC; Ando, T; Angelone, AM; Anglani, F; Ap, Y; Arthanari, SK; Axelrad, C; Bai, S; Bakonyi, P; Barnes, E; Beckmann, NA; Bélafi-Bakó, K; Bennett, CM; Bestha, RM; Bitsch, RG; Bradley, CA; Bu, Y; Calò, LA; Cañedo-Villaroya, E; Carlson, L; Caruso, S; Casado-Flores, J; Ceol, M; Cesarino, I; Chen, IL; Chen, R; Chen, X; Chilvers, MI; Cho, WK; Choong, TSY; Conceição-Neto, N; Culver, EL; Dai, X; de Lama Caro-Patón, G; De Rosa, I; Del Prete, D; Dharmage, SC; Dimitriadis, E; Dittakavi, S; Dobrowolski, JC; Edin, S; Elgarawany, GE; Emam, HE; Emmens, RW; Erbas, B; Erwich, JJHM; Farghali, M; Feng, L; Funston, RN; Gabler, NK; Gale, P; Ganesh, M; Gao, J; Gao, L; Gao, X; García-Salido, A; Gatto, R; Gautam, S; Ge, C; Ghogomu, SM; Gianesello, L; Gonçales, VR; Gooch, JL; Gooding, JJ; Gourley, GG; Gu, H; Gu, X; Gu, Z; Guerreri, M; Guillén, M; Hazzaa, SM; Heylen, E; Hicks, R; Hong, X; Hoshi, M; Hu, B; Hu, LX; Hu, R; Hu, S; Huang, J; Huang, K; Hubbard, WB; Hui, J; Hwang, NY; Iannacci, J; Ianus, A; Iglesias-Bouzas, MI; Ihara, I; Iwasaki, M; Jaeger, S; Kandel, YR; Karpińska, G; Kim, HK; Klopfenstein, TJ; Knorr, D; Koók, L; Kotb, S; Kruithof, S; Larsson, P; Laurence, C; Leng, J; Li, H; Li, J; Li, Q; Li, S; Li, X; Li, Z; Lian, J; Liang, JX; Liang, X; Lighaam, LC; Lin, CW; Lin, HC; Lin, J; Ling, A; Liu, J; Liu, P; Liu, YS; Ljuslinder, I; Lo, GH; Lodge, CJ; Löfgren-Burström, A; Lowe, AJ; Lu, M; Lu, N; Lucero-Prisno, DE; Luebbe, KM; Luo, X; Ma, Z; Maes, P; Makuch, M; Malekbala, MR; Mao, Z; Martínez-Romera, I; Marzo, G; Mathew, FM; Mattei, A; Matthijnssens, J; Mayumi, M; Morita, N; Mueller, DS; Mullangi, R; Mummolo, S; Murthi, P; Myte, R; Nabeshima, T; Nakamoto, K; Nehdi, IA; Nemestóthy, N; Niessen, HWM; Noh, JM; Nota, A; Nunes, D; Oh, D; Öhlund, D; Olsen, KM; Ono, H; Osawa, Y; Palmqvist, R; Palombo, M; Park, M; Patience, JF; Peng, Y; Perng, DS; Persano, A; Priante, G; Prince, SJ; Pulipati, S; Pyo, H; Qiu, X; Quan, J; Quaranta, F; Quinzi, V; Rademacher, CJ; Rajaraman, G; Rashid, U; Rauch, JC; Rector, A; Remmerswaal, EBM; Ren, R; Rispens, T; Rocha, GS; Saad, NM; Saito, K; Salamova, A; Sarfaraz, K; Satoshi, A; Schnellmann, RG; Scholpa, NE; Schonhoff, M; Schwartz, KJ; Schwarze, M; Schweer, WP; Seiichi, Y; Serrano-González, A; Severino, J; Shemesh, N; Shi, ZQ; Shike, DW; Shim, YM; Siciliano, PA; Siebenrock, KA; Silva, MKL; Smith, DL; Soltani, S; Song, YM; Spry, ML; Stalker, LA; Stokes, RS; Sullivan, PG; Sun, JM; Sun, S; Svanes, C; Syo, K; Tai, CM; Takashima, S; Tashita, C; Taurino, A; Ten Berge, IJM; Tenuta, AU; Teo, SH; Tilley, RD; Trivedi, RK; Umetsu, K; Unger, PA; van Bruggen, R; van Ham, SM; Van Ranst, M; Vanitha, J; Vekaria, HJ; Venier, M; Venkateshwaran, K; Venkert, A; Vermeulen, E; Wan, C; Wang, H; Wang, N; Wang, P; Wang, T; Wang, X; Wang, Y; Wise, KA; Wolbink, GJ; Wu, J; Wu, P; Wu, S; Wu, Y; Xia, Q; Xin, W; Xiong, Q; Xu, H; Xu, P; Xue, S; Yamamoto, Y; Yamashiro, T; Yan, F; Yan, H; Yan, S; Yan, Y; Yang, JM; Yang, L; Yang, P; Ye, W; Yeh, JH; Yinda, CK; Ying, GG; Ying, L; Yoon, HG; Yu, H; Zainuddin, M; Zakkula, A; Zeller, M; Zeng, Y; Zha, J; Zhang, F; Zhang, H; Zhang, M; Zhang, Q; Zhang, S; Zhang, T; Zhang, Z; Zhao, C; Zhao, J; Zhao, Y; Zhong, Q; Zhu, J; Zingmark, C; Zo, JI; Zou, Y | 1 |
| Gyu Song, G; Ho Lee, Y | 1 |
| Singh, S | 1 |
| Lee, YH; Sung, YK | 1 |
| IJzerman, AP; Jacobson, KA; Müller, CE | 1 |
| Aletaha, D; Baraliakos, X; Boehncke, WH; de Wit, M; Dörner, T; Dougados, M; Emery, P; Fleischmann, RM; Geissler, K; Isaacs, JD; Kerschbaumer, A; Kremer, J; Lee, EB; Maksymowych, WP; McInnes, I; Nash, P; Pope, JE; Smolen, JS; Stoffer-Marx, M; Takeuchi, T; Tam, LS; Tanaka, Y; Trauner, M; van den Bosch, F; van der Heijde, D; Voshaar, M; Westhovens, R; Winthrop, KL; Xavier, R | 1 |
| Adas, M; Bechman, K; Cope, AP; Galloway, JB; Mootoo, A; Norton, S; Patel, V; Qureshi, S; Rampes, S; Yates, M | 1 |
| Amano, K; Atsumi, T; Bartok, B; de Vlam, K; Gao, J; Genovese, MC; Gottenberg, JE; Guo, Y; Ishiguro, N; Kalunian, K; Kondo, A; Matsubara, T; Pechonkina, A; Sugiyama, E; Sundy, JS; Takeuchi, T; Tanaka, Y; Tasset, C; Walker, D; Yamaoka, K | 1 |
| Atsumi, T; Bartok, B; Burmester, GR; Ching, DWT; Chopra, A; Guo, Y; Jahreis, A; Kay, J; Landewé, RB; Matzkies, F; Messina, OD; Mozaffarian, N; Rigby, WFC; Stohl, W; Sundy, JS; Tasset, C; van der Heijde, D; Westhovens, R; Yin, Z | 1 |
| Bae, SC; Baraf, HSB; Bartok, B; Combe, B; Genovese, MC; Guo, Y; Jahreis, A; Keystone, EC; Kivitz, A; Kumar, U; Landewé, RBM; Matzkies, F; Mozaffarian, N; Nash, P; Simon, JA; Sundy, JS; Tanaka, Y; Tasset, C; van der Heijde, D; Ye, L | 1 |
| Alten, R; An, D; Besuyen, R; Genovese, MC; Greenwald, M; Kavanaugh, A; Lee, SJ; Meuleners, L; Spindler, AJ; Stanislavchuk, M; Sundy, JS; Tan, Y; Westhovens, RR; Winthrop, KL; Ye, L | 1 |
| Cribbs, AP; Feldmann, M; Filippakopoulos, P; Oerum, H; Oppermann, U; Penn, H; Philpott, M; Valge-Archer, V; Wells, G | 1 |
| Berger, S; Burriss, SW; Peterfy, C; Quattrocchi, E; Siddall, H; Tak, PP; Taylor, PC; Thorn, K; Tompson, D; Walter, J; Wang, S; Weisel, K | 1 |
| Kavanaugh, A; McInnes, IB; Tanaka, Y; Wicklund, J | 1 |
| Campigotto, F; Di Paolo, JA; Galien, R; Meng, A; Murray, B; Traves, PG | 1 |
| Biggioggero, M; Caporali, R; Coletto, LA; Favalli, EG; Raimondo, MG; Ramming, A | 1 |
| Lizarraga, A; Mysler, E | 1 |
| Avci, AB; Burmester, GR; Feist, E | 1 |
| Nash, P | 1 |
| Adas, M; Bechman, K; Clarke, B; Galloway, J; Yates, M | 1 |
| Keam, SJ; Kim, ES | 1 |
| Adami, G; Aletaha, D; Bartok, B; Bird, P; Buch, MH; Burmester, GR; Gaujoux-Viala, C; Guo, Y; Hendrikx, T; Matsumoto, A; Messina, OD; Westhovens, R; Yin, Z | 1 |
| Richez, C; Truchetet, ME | 1 |
| Ahmadu, C; Armstrong, N; Brandts, L; Fayter, D; Grimm, SE; Joore, MA; Kirwan, JR; Kleijnen, J; Misso, K; Riemsma, R; Wijnen, B | 1 |
| Galien, R; Mazur, M; Meuleners, L; Namour, F; Stanislavchuk, M; van 't Klooster, G; Van der Aa, A; Vanhoutte, F; Voloshyn, O | 1 |
| Abdul Azeez, M; Kiriakidis, S; Taylor, PC | 1 |
| Chen, L; Li, D; Wu, X; Zhong, J | 1 |
| Genovese, M; Harrison, P; Kavanaugh, A; Meuleners, L; Tasset, C; Van der Aa, A; Westhovens, R | 1 |
| Gadina, M; O'Shea, JJ | 1 |
| Singh, JA | 1 |
| Bartok, B; de Vlam, K; Gao, J; Genovese, MC; Gottenberg, JE; Guo, Y; Kalunian, K; Matzkies, F; Mozaffarian, N; Sundy, JS; Takeuchi, T; Tasset, C; Walker, D | 1 |
| Akata, K; Aoki, T; Fujii, M; Hisaoka, M; Ishimoto, H; Kawanami, T; Kinoshita, S; Korogi, Y; Mukae, H; Yatera, K | 1 |
| Cox, E; Diderichsen, PM; Namour, F; Tasset, C; Van der Aa, A; Van't Klooster, G; Vayssière, B | 1 |
| Chen, C; Chen, W; Guo, L; Li, J; Luo, L; Wu, D; Ye, C; Yu, X; Zhang, D; Zhu, L | 1 |
| Qian, J; Zhang, QG; Zhu, YC | 1 |
| Srinivas, NR | 1 |
| Namour, F | 1 |
| Blanco, JR; Ochoa-Callejero, L | 1 |
| Iwata, S; Kubo, S; Nakayamada, S; Tanaka, Y | 1 |
| Alten, R; Enríquez-Sosa, F; Greenwald, M; Harrison, P; Mazur, M; Pavlova, D; Tasset, C; Taylor, PC; Van der Aa, A; Vanhoutte, F; Westhovens, R | 1 |
| Cseuz, R; Greenwald, M; Harrison, P; Kavanaugh, A; Kremer, J; Ponce, L; Reshetko, OV; Stanislavchuk, M; Tasset, C; Van der Aa, A; Vanhoutte, F | 1 |
| Moreno López, E; Rodríguez Losada, M; Roibal, MA; Sanduende Otero, Y | 1 |
| Chao, J; Parker, BA; Zvaifler, NJ | 1 |
| Bertolini, E; Letho-Gyselinck, H; Prati, C; Wendling, D | 1 |
| Albom, MS; Angeles, TS; Ator, MA; Dobrzanski, P; Dorsey, BD; Dugan, BJ; Gingrich, DE; Lu, LD; Ruggeri, BA; Seavey, MM; Serdikoff, C; Stump, KL | 1 |
| Fleishaker, DL; Garcia Meijide, JA; Goodrich, JM; Kohen, MD; Mayer, HB; Mebus, CA; Menon, S; Petrov, A; Stock, TC; Wang, X; Zeiher, BG | 1 |
| Cleary, JD; DeShazo, M; Jenkins, J; Songcharoen, S | 1 |
| Kameda, H; Takeuchi, T | 1 |
| Igaki, N; Yokota, K | 1 |
| Egger, M; Telenti, A | 1 |
| Jackson, V; McHale, M; Penny, M; Wheeler, J | 1 |
| Kadow, JF; Meanwell, NA | 1 |
| Chermat-Izard, V; Guinot, P; Hilliquin, P; Menkes, CJ; Puechal, X | 1 |
| Chermat-Izard, V; Hilliquin, P; Menkes, CJ | 1 |
| Egido, J; Gutierrez, S; Herrero-Beaumont, G; Miguélez, R; Palacios, I; Sánchez-Pernaute, O | 1 |
28 review(s) available for triazoles and Rheumatoid Arthritis
| Article | Year |
|---|---|
Filgotinib: A Clinical Pharmacology Review.
Topics: Arthritis, Rheumatoid; Humans; Janus Kinase Inhibitors; Pharmacology, Clinical; Pyridines; Triazoles | 2022 |
Filgotinib in rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Janus Kinase Inhibitors; Pyridines; Triazoles | 2023 |
Comparison of the efficacy and safety of tofacitinib and filgotinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Drug Therapy, Combination; Humans; Methotrexate; Network Meta-Analysis; Piperidines; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome; Triazoles | 2020 |
Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis.
Topics: Arthritis, Rheumatoid; Azetidines; Herpes Zoster; Heterocyclic Compounds, 3-Ring; Humans; Incidence; Inflammatory Bowel Diseases; Janus Kinase Inhibitors; Janus Kinases; Piperidines; Placebos; Psoriasis; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Spondylitis, Ankylosing; Sulfonamides; Survival Analysis; Treatment Outcome; Triazoles | 2020 |
Topics: Acetaminophen; Administration, Oral; Adolescent; Adsorption; Adult; Allyl Compounds; Amylopectin; Amylose; Anaerobiosis; Animals; Anti-Bacterial Agents; Anura; Arginase; Arthritis, Rheumatoid; Asthma; Atmosphere; B-Lymphocytes; Basic Helix-Loop-Helix Transcription Factors; Bioelectric Energy Sources; Biofilms; Biofuels; Biomarkers; Biopolymers; Bioreactors; Brain; Brain Injuries, Traumatic; Breast Neoplasms; Calibration; Carbon Tetrachloride; Caspase 3; Catalysis; Catechin; Cations; Cattle; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Body; Cell Line, Tumor; Cell Plasticity; Chemical and Drug Induced Liver Injury; Chemistry Techniques, Synthetic; China; Chitosan; Chloride Channels; Chromatography, High Pressure Liquid; Chromosome Mapping; Cognition; Cognitive Dysfunction; Cohort Studies; Colitis, Ulcerative; Colloids; Coloring Agents; Congresses as Topic; Correlation of Data; Crystallization; Cyanoacrylates; Cyclohexane Monoterpenes; Cyprinidae; Cytochrome P-450 CYP1A1; Death, Sudden; Dent Disease; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Disease Models, Animal; Disease Progression; Disease Resistance; Disulfides; Drug Monitoring; Drug Stability; Ecotoxicology; Electricity; Electrodes; Endocytosis; Environmental Exposure; Environmental Monitoring; Enzyme Inhibitors; Epithelial-Mesenchymal Transition; Esophageal and Gastric Varices; Esters; Fagopyrum; Female; Ferrosoferric Oxide; Flame Retardants; Flavobacteriaceae; Flow Cytometry; Follow-Up Studies; Formoterol Fumarate; Fusarium; Garlic; Gastrointestinal Hemorrhage; Gene Expression; Genes, Plant; Genetic Markers; Glial Fibrillary Acidic Protein; Gliosis; Global Health; Glutathione Transferase; Glycine max; Gum Arabic; Hemostasis, Endoscopic; Hepatocytes; Hippocampus; Humans; Hydrogen-Ion Concentration; Illinois; Immunoglobulin G; Indoleamine-Pyrrole 2,3,-Dioxygenase; Infant, Newborn; Infant, Small for Gestational Age; Injections, Intraperitoneal; Interleukin-4; Iowa; Iron; Ki-67 Antigen; Kidney; Kinetics; Kynurenine; Lakes; Levofloxacin; Lipid Peroxidation; Lipids; Liver; Liver Cirrhosis, Experimental; Magnetic Fields; Magnetic Iron Oxide Nanoparticles; Male; Manure; Maze Learning; Memory, Short-Term; Metal Nanoparticles; Metals, Heavy; Methane; Mice; Mice, Inbred C57BL; Mice, Knockout; Michigan; Microalgae; Microbial Consortia; Mitochondria; Models, Animal; Models, Chemical; Models, Neurological; Molecular Structure; Molecular Weight; Mutation; Myeloid-Derived Suppressor Cells; NADPH Oxidase 2; Neoplasm Recurrence, Local; Neurites; Neurons; Neuroprotective Agents; NF-kappa B; NIH 3T3 Cells; Nitric Oxide Synthase Type II; Nitrogen; Ohio; Ointments; Ontario; Organelle Biogenesis; Organophosphates; Organophosphorus Compounds; Oxidative Stress; Palladium; Particle Size; Pectins; Phenotype; Phytotherapy; Piperidines; Placenta; Plant Diseases; Plant Extracts; Polymers; Polymorphism, Genetic; Polyphenols; Powders; Pregnancy; Pregnancy Trimester, First; Prospective Studies; Protein Kinase Inhibitors; Protein Structure, Secondary; Proteins; Pyridines; Pyrimidines; Rats, Wistar; Real-Time Polymerase Chain Reaction; Receptors, Aryl Hydrocarbon; Receptors, Chemokine; Receptors, Formyl Peptide; Receptors, Lipoxin; Recovery of Function; Recurrence; Reference Standards; Reference Values; Reproducibility of Results; Respiratory Function Tests; Retrospective Studies; Risk; Sensitivity and Specificity; Sewage; Signal Transduction; Sodium Glutamate; Soil; Solanum tuberosum; Solubility; Solutions; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spermatozoa; STAT3 Transcription Factor; Sulfamethoxazole; Tea; Temperature; Thermodynamics; Thrombin; Treatment Outcome; Triazoles; United States; Viscosity; Waste Disposal, Fluid; Wastewater; Water; Water Pollutants, Chemical; Water Purification; White Matter; Wisconsin; X-Ray Diffraction; Zea mays | 2013 |
Comparative efficacy and safety of 100 mg and 200 mg filgotinib administered to patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials
.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Drug Therapy, Combination; Humans; Janus Kinase 1; Methotrexate; Network Meta-Analysis; Pyridines; Randomized Controlled Trials as Topic; Treatment Outcome; Triazoles | 2020 |
Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Biological Products; Heterocyclic Compounds, 3-Ring; Humans; Methotrexate; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sulfonamides; Treatment Outcome; Triazoles | 2021 |
Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis.
Topics: Adamantane; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Bayes Theorem; Heterocyclic Compounds, 3-Ring; Humans; Niacinamide; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Randomized Controlled Trials as Topic; Sulfonamides; Triazoles | 2020 |
JAK-STAT inhibitors: Immersing therapeutic approach for management of rheumatoid arthritis.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Clinical Trials as Topic; Cytokines; Humans; Inflammation; Janus Kinase Inhibitors; Janus Kinases; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyridines; Signal Transduction; STAT Transcription Factors; Sulfonamides; Triazoles | 2020 |
Comparative study of the efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib versus methotrexate for disease-modifying antirheumatic drug-naïve patients with rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Bayes Theorem; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; Humans; Methotrexate; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Sulfonamides; Treatment Outcome; Triazoles | 2021 |
Medicinal chemistry of P2 and adenosine receptors: Common scaffolds adapted for multiple targets.
Topics: Animals; Arthritis, Rheumatoid; Chemistry, Pharmaceutical; Chronic Pain; Drug Delivery Systems; Humans; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Purinergic P2 Receptor Agonists; Purinergic P2 Receptor Antagonists; Pyridines; Receptors, Purinergic P1; Receptors, Purinergic P2; Triazoles | 2021 |
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement.
Topics: Adamantane; Advisory Committees; Antirheumatic Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Azetidines; Cytokines; Drug Therapy, Combination; Europe; Heterocyclic Compounds, 3-Ring; Humans; Inflammatory Bowel Diseases; Janus Kinase Inhibitors; Niacinamide; Piperidines; Psoriasis; Purines; Pyrazoles; Pyridines; Pyrimidines; Rheumatology; Spondylarthropathies; Spondylitis, Ankylosing; Sulfonamides; Triazoles | 2021 |
Venous Thromboembolism Risk With JAK Inhibitors: A Meta-Analysis.
Topics: Arthritis, Psoriatic; Arthritis, Rheumatoid; Azetidines; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Heterocyclic Compounds, 3-Ring; Humans; Inflammatory Bowel Diseases; Janus Kinase Inhibitors; Piperidines; Psoriasis; Pulmonary Embolism; Purines; Pyrazoles; Pyridines; Pyrimidines; Randomized Controlled Trials as Topic; Risk; Spondylarthropathies; Spondylitis, Ankylosing; Sulfonamides; Triazoles; Venous Thromboembolism; Venous Thrombosis | 2021 |
Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: An overview from clinical trials.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Janus Kinase 1; Janus Kinase Inhibitors; Pyridines; Triazoles | 2022 |
Clinical pharmacology of filgotinib in the treatment of rheumatoid arthritis: current insights.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Janus Kinase 1; Janus Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Triazoles | 2021 |
Phase III trials of JAK1 selective inhibitors in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Clinical Trials, Phase III as Topic; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase 1; Janus Kinase Inhibitors; Pyridines; Treatment Outcome; Triazoles | 2021 |
Early phase studies of JAK1 selective inhibitors in rheumatoid arthritis.
Topics: Acetonitriles; Arthritis, Rheumatoid; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase 1; Janus Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Triazoles | 2021 |
Clinical use of Jak 1 inhibitors for rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase 1; Janus Kinase Inhibitors; Methotrexate; Practice Patterns, Physicians'; Pyridines; Triazoles | 2021 |
The safety of JAK-1 inhibitors.
Topics: Arthritis, Rheumatoid; Chemical and Drug Induced Liver Injury; Diverticular Diseases; Herpes Simplex; Herpes Zoster; Heterocyclic Compounds, 3-Ring; Humans; Immunocompromised Host; Infections; Intestinal Perforation; Janus Kinase 1; Janus Kinase Inhibitors; Latent Infection; Opportunistic Infections; Pyridines; Triazoles | 2021 |
Filgotinib in Rheumatoid Arthritis: A Profile of Its Use.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Pyridines; Triazoles | 2021 |
Evaluating filgotinib for the treatment of rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Pyridines; Triazoles | 2021 |
Filgotinib for Moderate to Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Topics: Arthritis, Rheumatoid; Cost-Benefit Analysis; Humans; Pyridines; Quality-Adjusted Life Years; Technology; Technology Assessment, Biomedical; Triazoles | 2021 |
Filgotinib for the treatment of rheumatoid arthritis.
Topics: Administration, Oral; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Design; Humans; Janus Kinase 1; Molecular Targeted Therapy; Protein Kinase Inhibitors; Pyridines; Triazoles | 2017 |
Clinical efficacy of new JAK inhibitors under development. Just more of the same?
Topics: Adamantane; Arthritis, Rheumatoid; Azetidines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase 1; Janus Kinase 3; Janus Kinase Inhibitors; Niacinamide; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sulfonamides; Treatment Outcome; Triazoles; Valine | 2019 |
Off-label use of maraviroc in clinical practice.
Topics: Animals; Arthritis, Rheumatoid; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Graft vs Host Disease; Hematologic Neoplasms; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Mice; Off-Label Use; Sarcoidosis; Triazoles | 2016 |
Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinases; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sulfonamides; Triazoles | 2016 |
Assessing theoretical risk and benefit suggested by genetic association studies of CCR5: experience in a drug development programme for maraviroc.
Topics: Adult; Arthritis, Rheumatoid; CCR5 Receptor Antagonists; Cyclohexanes; Drug Design; Female; Genotype; Hepatitis C; HIV Fusion Inhibitors; HIV Infections; Humans; Male; Maraviroc; Multiple Sclerosis; Mutation; Pharmacogenetics; Receptors, CCR5; Risk Assessment; Risk Factors; Triazoles | 2007 |
Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS.
Topics: Acquired Immunodeficiency Syndrome; Animals; Anti-HIV Agents; Anti-Inflammatory Agents; Arthritis, Rheumatoid; CCR5 Receptor Antagonists; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclohexanes; HIV Infections; Humans; Maraviroc; Receptors, CCR5; Structure-Activity Relationship; Triazoles | 2007 |
20 trial(s) available for triazoles and Rheumatoid Arthritis
| Article | Year |
|---|---|
Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1).
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Finches; Humans; Japan; Methotrexate; Pyridines; Treatment Outcome; Triazoles | 2022 |
Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3)
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Finches; Humans; Japan; Methotrexate; Pyridines; Treatment Outcome; Triazoles | 2022 |
The impact of filgotinib on patient-reported outcomes and health-related quality of life for patients with active rheumatoid arthritis: a post hoc analysis of Phase 3 studies.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Humans; Methotrexate; Patient Reported Outcome Measures; Pyridines; Quality of Life; Treatment Outcome; Triazoles | 2022 |
Exposure-response relationships for the efficacy and safety of filgotinib and its metabolite GS-829845 in subjects with rheumatoid arthritis based on phase 2 and phase 3 studies.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Janus Kinase Inhibitors; Pyridines; Treatment Outcome; Triazoles | 2022 |
Topics: Acetaminophen; Administration, Oral; Adolescent; Adsorption; Adult; Allyl Compounds; Amylopectin; Amylose; Anaerobiosis; Animals; Anti-Bacterial Agents; Anura; Arginase; Arthritis, Rheumatoid; Asthma; Atmosphere; B-Lymphocytes; Basic Helix-Loop-Helix Transcription Factors; Bioelectric Energy Sources; Biofilms; Biofuels; Biomarkers; Biopolymers; Bioreactors; Brain; Brain Injuries, Traumatic; Breast Neoplasms; Calibration; Carbon Tetrachloride; Caspase 3; Catalysis; Catechin; Cations; Cattle; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Body; Cell Line, Tumor; Cell Plasticity; Chemical and Drug Induced Liver Injury; Chemistry Techniques, Synthetic; China; Chitosan; Chloride Channels; Chromatography, High Pressure Liquid; Chromosome Mapping; Cognition; Cognitive Dysfunction; Cohort Studies; Colitis, Ulcerative; Colloids; Coloring Agents; Congresses as Topic; Correlation of Data; Crystallization; Cyanoacrylates; Cyclohexane Monoterpenes; Cyprinidae; Cytochrome P-450 CYP1A1; Death, Sudden; Dent Disease; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Disease Models, Animal; Disease Progression; Disease Resistance; Disulfides; Drug Monitoring; Drug Stability; Ecotoxicology; Electricity; Electrodes; Endocytosis; Environmental Exposure; Environmental Monitoring; Enzyme Inhibitors; Epithelial-Mesenchymal Transition; Esophageal and Gastric Varices; Esters; Fagopyrum; Female; Ferrosoferric Oxide; Flame Retardants; Flavobacteriaceae; Flow Cytometry; Follow-Up Studies; Formoterol Fumarate; Fusarium; Garlic; Gastrointestinal Hemorrhage; Gene Expression; Genes, Plant; Genetic Markers; Glial Fibrillary Acidic Protein; Gliosis; Global Health; Glutathione Transferase; Glycine max; Gum Arabic; Hemostasis, Endoscopic; Hepatocytes; Hippocampus; Humans; Hydrogen-Ion Concentration; Illinois; Immunoglobulin G; Indoleamine-Pyrrole 2,3,-Dioxygenase; Infant, Newborn; Infant, Small for Gestational Age; Injections, Intraperitoneal; Interleukin-4; Iowa; Iron; Ki-67 Antigen; Kidney; Kinetics; Kynurenine; Lakes; Levofloxacin; Lipid Peroxidation; Lipids; Liver; Liver Cirrhosis, Experimental; Magnetic Fields; Magnetic Iron Oxide Nanoparticles; Male; Manure; Maze Learning; Memory, Short-Term; Metal Nanoparticles; Metals, Heavy; Methane; Mice; Mice, Inbred C57BL; Mice, Knockout; Michigan; Microalgae; Microbial Consortia; Mitochondria; Models, Animal; Models, Chemical; Models, Neurological; Molecular Structure; Molecular Weight; Mutation; Myeloid-Derived Suppressor Cells; NADPH Oxidase 2; Neoplasm Recurrence, Local; Neurites; Neurons; Neuroprotective Agents; NF-kappa B; NIH 3T3 Cells; Nitric Oxide Synthase Type II; Nitrogen; Ohio; Ointments; Ontario; Organelle Biogenesis; Organophosphates; Organophosphorus Compounds; Oxidative Stress; Palladium; Particle Size; Pectins; Phenotype; Phytotherapy; Piperidines; Placenta; Plant Diseases; Plant Extracts; Polymers; Polymorphism, Genetic; Polyphenols; Powders; Pregnancy; Pregnancy Trimester, First; Prospective Studies; Protein Kinase Inhibitors; Protein Structure, Secondary; Proteins; Pyridines; Pyrimidines; Rats, Wistar; Real-Time Polymerase Chain Reaction; Receptors, Aryl Hydrocarbon; Receptors, Chemokine; Receptors, Formyl Peptide; Receptors, Lipoxin; Recovery of Function; Recurrence; Reference Standards; Reference Values; Reproducibility of Results; Respiratory Function Tests; Retrospective Studies; Risk; Sensitivity and Specificity; Sewage; Signal Transduction; Sodium Glutamate; Soil; Solanum tuberosum; Solubility; Solutions; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spermatozoa; STAT3 Transcription Factor; Sulfamethoxazole; Tea; Temperature; Thermodynamics; Thrombin; Treatment Outcome; Triazoles; United States; Viscosity; Waste Disposal, Fluid; Wastewater; Water; Water Pollutants, Chemical; Water Purification; White Matter; Wisconsin; X-Ray Diffraction; Zea mays | 2013 |
Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global phase 3 study (FINCH 2).
Topics: Adult; Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Finches; Humans; Japan; Methotrexate; Pyridines; Treatment Outcome; Triazoles | 2022 |
Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Finches; Humans; Methotrexate; Pyridines; Treatment Outcome; Triazoles | 2021 |
Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial.
Topics: Adalimumab; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Pyridines; Triazoles | 2021 |
Safety and Efficacy of Filgotinib: Up to 4-year Results From an Open-label Extension Study of Phase II Rheumatoid Arthritis Programs.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Humans; Male; Methotrexate; Pyridines; Treatment Outcome; Triazoles | 2021 |
A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biomedical Research; Double-Blind Method; Humans; Oxazepines; Receptor-Interacting Protein Serine-Threonine Kinases; Treatment Outcome; Triazoles | 2021 |
Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Methotrexate; Prognosis; Pyridines; Treatment Outcome; Triazoles | 2021 |
Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Janus Kinase 1; Male; Methotrexate; Middle Aged; Pyridines; Treatment Outcome; Triazoles; Young Adult | 2017 |
Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Janus Kinase 1; Male; Methotrexate; Middle Aged; Patient Reported Outcome Measures; Protein Kinase Inhibitors; Pyridines; Treatment Outcome; Triazoles | 2018 |
Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; C-Reactive Protein; Dose-Response Relationship, Drug; Double-Blind Method; Drug Tolerance; Female; Hematologic Tests; Humans; Infections; Janus Kinase 1; Male; Middle Aged; Pyridines; Remission Induction; Severity of Illness Index; Triazoles | 2019 |
Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Double-Blind Method; Healthy Volunteers; Humans; Janus Kinase 1; Male; Middle Aged; Phosphorylation; Pyridines; Triazoles | 2015 |
Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1).
Topics: Administration, Oral; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Disability Evaluation; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Hemoglobins; Humans; Infections; Janus Kinase 1; Male; Methotrexate; Middle Aged; Protein Kinase Inhibitors; Pyridines; Severity of Illness Index; Surveys and Questionnaires; Triazoles | 2017 |
Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2).
Topics: Administration, Oral; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Disability Evaluation; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hemoglobins; Humans; Infections; Janus Kinase 1; Male; Methotrexate; Middle Aged; Protein Kinase Inhibitors; Pyridines; Retreatment; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome; Triazoles | 2017 |
Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Area Under Curve; Arthritis, Rheumatoid; CCR5 Receptor Antagonists; Constipation; Cyclohexanes; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Maraviroc; Metabolic Clearance Rate; Methotrexate; Middle Aged; Nausea; Treatment Failure; Triazoles; Young Adult | 2012 |
Treatment of rheumatoid arthritis with platelet activating factor antagonist BN 50730.
Topics: Adult; Aged; Arthritis, Rheumatoid; Azepines; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Severity of Illness Index; Thienopyridines; Treatment Outcome; Triazoles | 1995 |
A double blind, placebo controlled study of a platelet activating factor antagonist in patients with rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Azepines; Double-Blind Method; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Platelet Activating Factor; Platelet Aggregation Inhibitors; Thienopyridines; Treatment Outcome; Triazoles | 1998 |
23 other study(ies) available for triazoles and Rheumatoid Arthritis
| Article | Year |
|---|---|
Filgotinib as rheumatoid arthritis therapy.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Pyridines; Triazoles | 2021 |
Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Janus Kinase Inhibitors; Pyridines; Triazoles | 2022 |
Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Cell Line; Cytokines; Enzyme Assays; Female; Healthy Volunteers; Heterocyclic Compounds, 3-Ring; Humans; Inhibitory Concentration 50; Janus Kinase 1; Janus Kinase Inhibitors; Male; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Receptors, Cytokine; Sulfonamides; Triazoles | 2019 |
Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis.
Topics: Adalimumab; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Bayes Theorem; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; Humans; Methotrexate; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sulfonamides; Treatment Outcome; Triazoles | 2020 |
Dissecting the Role of BET Bromodomain Proteins BRD2 and BRD4 in Human NK Cell Function.
Topics: Arthritis, Rheumatoid; Azepines; Cell Cycle Proteins; Cytokines; Healthy Volunteers; Heterocyclic Compounds, 2-Ring; High-Throughput Nucleotide Sequencing; Humans; Inflammation; Killer Cells, Natural; Piperazines; Pyrazoles; Pyridazines; Transcription Factors; Transcriptome; Triazoles | 2021 |
JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Cells, Cultured; Cytokines; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase Inhibitors; Janus Kinases; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Sulfonamides; Triazoles | 2021 |
L161982 alleviates collagen-induced arthritis in mice by increasing Treg cells and down-regulating Interleukin-17 and monocyte-chemoattractant protein-1 levels.
Topics: Animals; Ankle Joint; Arthritis, Experimental; Arthritis, Rheumatoid; Celecoxib; Cell Differentiation; Cell Proliferation; Chemokine CCL2; Collagen Type II; Cyclooxygenase 2 Inhibitors; Dinoprostone; Down-Regulation; Female; Humans; Injections, Intraperitoneal; Interleukin-17; Mice; Mice, Inbred DBA; Receptors, Prostaglandin E, EP4 Subtype; Severity of Illness Index; Signal Transduction; T-Lymphocytes, Regulatory; Th17 Cells; Thiophenes; Triazoles | 2017 |
Selective Janus kinase inhibitors come of age.
Topics: Arthritis, Psoriatic; Arthritis, Rheumatoid; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase Inhibitors; Pyridines; Triazoles | 2019 |
Filgotinib, a JAK1 Inhibitor, for Treatment-Resistant Rheumatoid Arthritis.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Finches; Humans; Janus Kinase 1; Pyridines; Triazoles | 2019 |
Disseminated pulmonary penicilliosis in a rheumatoid arthritis patient.
Topics: Amphotericin B; Anti-Inflammatory Agents; Antifungal Agents; Arthritis, Rheumatoid; Diagnosis, Differential; Echinocandins; Humans; Hydrocortisone; Lipopeptides; Lung; Lung Diseases, Fungal; Male; Micafungin; Middle Aged; Pyrimidines; Tomography, X-Ray Computed; Treatment Outcome; Triazoles; Voriconazole | 2014 |
Activation of NALP1 inflammasomes in rats with adjuvant arthritis; a novel therapeutic target of carboxyamidotriazole in a model of rheumatoid arthritis.
Topics: Animals; Ankle Joint; Anti-Inflammatory Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Cytokines; Inflammasomes; Male; Nerve Tissue Proteins; Radiography; Rats, Inbred Lew; Synovial Membrane; Triazoles | 2015 |
Targeting bromodomain-containing protein 4 (BRD4) benefits rheumatoid arthritis.
Topics: Animals; Apoptosis; Arthritis, Experimental; Arthritis, Rheumatoid; Autoantibodies; Azepines; Cell Cycle Proteins; Cell Movement; Cell Proliferation; Cell Survival; Complement C2; Cytokines; Disease Models, Animal; Gene Expression; Gene Targeting; Humans; Inflammation Mediators; JNK Mitogen-Activated Protein Kinases; Mice; NF-kappa B; Nuclear Proteins; RNA Interference; RNA, Small Interfering; Transcription Factors; Transfection; Triazoles | 2015 |
Comment on: "Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modelling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection".
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Male; Pyridines; Triazoles | 2015 |
Author's Reply to Srinivas: "Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection".
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Male; Pyridines; Triazoles | 2015 |
[Amphotericin and posaconazole for gastrointestinal mucormycosis].
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adult; Amphotericin B; Anti-Bacterial Agents; Antifungal Agents; Arthritis, Rheumatoid; Colitis, Ulcerative; Combined Modality Therapy; Drainage; Fatal Outcome; Gastrointestinal Diseases; Humans; Ileal Diseases; Intestinal Perforation; Intraoperative Complications; Jejunal Diseases; Liposomes; Male; Mucormycosis; Peritonitis; Postoperative Complications; Shock, Septic; Triazoles | 2009 |
Accelerated cutaneous nodulosis associated with aromatase inhibitor therapy in a patient with rheumatoid arthritis.
Topics: Aged; Antineoplastic Agents; Aromatase Inhibitors; Arthritis, Rheumatoid; Breast Neoplasms; Female; Hand; Humans; Letrozole; Nitriles; Rheumatoid Nodule; Triazoles | 2009 |
Rheumatoid arthritis and aromatase inhibitors.
Topics: Adenocarcinoma; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Arthritis, Rheumatoid; Breast Neoplasms; Carcinoma, Ductal; Combined Modality Therapy; Female; Humans; Letrozole; Middle Aged; Nitriles; Triazoles | 2011 |
A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Blotting, Western; Disease Models, Animal; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Female; Janus Kinase 2; Mice; Mice, Inbred DBA; Pyridines; Triazoles | 2011 |
T. asahii pulmonary infection as a complication of TNF-inhibitor and steroids: posaconazole pharmacotherapy and risk analysis.
Topics: Adalimumab; Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antifungal Agents; Arthritis, Rheumatoid; Female; Glucocorticoids; Graft vs Host Disease; Humans; Immunosuppressive Agents; Infliximab; Lung Diseases, Fungal; Male; Middle Aged; Risk Assessment; Risk Factors; Root Cause Analysis; Triazoles; Trichosporonosis; Tumor Necrosis Factor Inhibitors; Young Adult | 2011 |
What is the future of CCR5 antagonists in rheumatoid arthritis?
Topics: Arthritis, Rheumatoid; Cyclohexanes; Female; Humans; Male; Methotrexate; Triazoles | 2012 |
Sitagliptin (DPP-4 inhibitor)-induced rheumatoid arthritis in type 2 diabetes mellitus: a case report.
Topics: Alleles; Arthritis, Rheumatoid; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Genetic Predisposition to Disease; HLA-DRB1 Chains; Humans; Middle Aged; Pyrazines; Rheumatoid Factor; Sitagliptin Phosphate; Triazoles | 2012 |
Identifying safety concerns from genetic data: lessons from the development of CCR5 inhibitors.
Topics: Arthritis, Rheumatoid; CCR5 Receptor Antagonists; Cyclohexanes; Drug Design; Genotype; Hepatitis C; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Meta-Analysis as Topic; Multiple Sclerosis; Mutation; Pharmacogenetics; Receptors, CCR5; Research Design; Risk Assessment; Risk Factors; Triazoles | 2007 |
A platelet activating factor receptor antagonist prevents the development of chronic arthritis in mice.
Topics: Animals; Arthritis, Rheumatoid; Azepines; Collagen; Disease Models, Animal; Female; Fibronectins; Immunohistochemistry; Joints; Mice; Mice, Inbred DBA; Platelet Aggregation Inhibitors; Platelet Membrane Glycoproteins; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Thienopyridines; Triazoles | 1999 |